ITRI's Collabody, with its recombinant fusion platform for making protein drugs with multiple binding capabilities, solves this problem and enhances the therapeutic potency
in attacking cancer cells through cross-linking with the targets. With three target-binding domains, like an octopus that has multiple tentacles, it enables increased binding strength and cross-linking potency and features further improvements in the triple collagen peptide-scaffold and antibody fragment fusion technology included within Collabody.